The invention relates to dendritic cells, the NFκB signaling pathway of which has been manipulated by RNA transfection, to the manufacture thereof and to use thereof.

The present invention provides methods to promote the differentiation of pluripotent stem cells into insulin producing cells. In particular, the present invention provides a method to produce cells expressing markers characteristic of the pancreatic endocrine lineage that co-express NKX6.1 and insulin and minimal amounts of glucagon.

Methods of providing populations of NKT and/or γδ T cells, and their use, e.g., in therapies such as cancer immunotherapy.

The present disclosure provides a method and a platform for disrupting intracellular microtubules. The method and the platform of the present disclosure can accurately and quickly disrupt the microtubule structure in a specific area of a cell by adding a specific chemical small molecule or a specific wavelength of light. In addition to providing important reagents for microtubule-related research in basic science, it may even be developed into a new technology for precise chemotherapy.

The present invention is provides a method for treating human pluripotent cells. In particular, the methods of the invention are directed to the treatment of human pluripotent cells, whereby the human pluripotent cells can be efficiently expanded in culture and differentiated by treating the pluripotent cells with an inhibitor of glycogen synthase kinase 3β (GSK-3B) enzyme activity.

The disclosure generally relates to methods and compositions for preparing a neural tissue construct. In particular, provided herein are methods for generating a neural tissue construct using glutamatergic cortical progenitor cells; GABAergic interneuron progenitor cells; and bio-ink.

The present invention provides a method for culturing odontoma cells or normal cells, wherein these cells are cultured in the presence of a Rho kinase inhibitor.

The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.

The present invention relates to a method for producing immune-compatible cells or a cell population which comprises a step of editing one or two alleles of one or more immune-compatible antigen genes by gene deletion or modification in an isolated cell comprising at least one of the immune-compatible antigen genes selected from HLA (human leukocyte antigen)-A, HLA-B and HLA-DR, to immune-compatible cells produced by the method, and to a cell population comprising the immune-compatible cells produced by the method

Several embodiments disclosed herein relate to methods and processes for the co-expansion of multiple types of immune cells, in order to generate a mixed cell population. Some embodiments relate to the use of various stimuli specific to the various subpopulations to achieve expansion of those subpopulations at a particular time in a culturing process in order to generate an expanded population of immune cells having a desired ratio of the various subpopulations. In several embodiments, such mixed cell populations exhibit desirable characteristics, such as cytotoxic effects against tumor cells that enhance the efficacy of cancer immunotherapy.